



Coronaviruses: Past, Present, and Future

Guest Editor:

Dr. Qibin Geng

Department of Pharmacology,
University of Minnesota,
Minneapolis, MN 55455, USA

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

Currently, the Omicron variant of SARS-CoV-2 and its subvariants, which are pretty different from the original strain or other previous variants in many respects. Omicron has the innate ability to evade the therapeutic antibodies and immune protection from prior COVID-19 infection and vaccination. Most worryingly, Omicron has shown no sign of slowing down and continues to rapidly mutate and generate new subvariants with immune-evasive properties like BA.5, BQ.1, BA.2.75.2, and XBB. Despite these headwinds, we have had vaccines and treatments available against COVID-19, despite reduced efficacy towards emerging variants. Improvements are still warranted toward the understanding of coronavirus infection and the new prophylaxis and therapeutic agents that can rapidly pivot to combat new viral variants or even new viruses that might drive the next pandemic.

For this Special Issue, we will be excited to see the advances, thoughts, and experiences related to the coronavirus family. Original research or review articles are warmly welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular
Systems Biology, UFZ-Helmholtz
Centre for Environmental
Research, 04318 Leipzig,
Germany

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*Microbiology (medical)*)

Contact Us

Microorganisms Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/microorganisms
microorganisms@mdpi.com
X@Micro_MDPI